A Phase 2 interventional study of busulfan and cyclophosphamide in Chronic Myeloproliferative Disorders, Graft Versus Host Disease and Leukemia, sponsored by City of Hope Medical Center. Active, not recruiting. Open to participants aged 0 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing busulfan in Myeloproliferative Disorders — 4 open to participants now, 6 under way, none of them phase 3. Busulfan · Myeloproliferative Disorders.
Among the 34 studies testing busulfan in Myeloproliferative Disorders, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2001, is one of 25 in phase 2, and was the 18th registered.
668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
Browse Myeloproliferative Disorders studies →4 of the 34 studies testing busulfan in Myeloproliferative Disorders are open now, in 3 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 21
Fred Hutchinson Cancer Center · Sites in United States
Ages 1–60
Institut Paoli-Calmettes
Ages 18–65
By country, each count listing its studies:
Busulfan: first FDA approval 1954 (MYLERAN), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 0 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 29 · Phase 3 3 · Phase 4 1
First in 1993; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 47 across 463 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 54 across the 31 interventional studies. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 34 has an industry lead sponsor. The 10 most frequent:
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
21 studies in Myeloproliferative Disorders by City of Hope Medical Center: 3 open now, 8 under way, none of them phase 3. Of 12 finished, 5 (42%) have results posted.
Among the 21 studies in Myeloproliferative Disorders by City of Hope Medical Center, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2001, is one of 12 in phase 2, and was the 2nd registered.
City of Hope Medical Center’s Myeloproliferative Disorders studies by the year they started, since 1999.
2 of the studies testing busulfan in Myeloproliferative Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies testing busulfan in Myeloproliferative Disorders, from their registry updates:
Among City of Hope Medical Center’s 21 in Myeloproliferative Disorders:
This tab as a report to print or save as PDF → With an account.
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus, methotrexate, cyclosporine, mycophenolate mofetil, and sirolimus before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant works in treating patients with advanced hematologic cancer or other disorders.
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients are stratified according to type of conditioning regimen (myeloablative vs reduced-intensity myeloablative). Patients are assigned to a conditioning regimen according to diagnosis, age, disease status, prior radiotherapy, and prior autologous stem cell transplantation.
Conditioning regimen:
Graft-versus-host disease (GVHD) prophylaxis: Patients receive one of the following GVHD prophylaxis regimens:
After completion of study therapy, patients are followed periodically.
DISEASE CHARACTERISTICS:
Diagnosis of one of the following:
Acute lymphocytic leukemia (ALL), meeting one of the following criteria:
High-risk ALL, defined by any of the following:
Acute myeloid leukemia (AML), meeting one of the following criteria:
Secondary AML (> 30% blasts in marrow aspirate)
Chronic myelogenous leukemia, meeting one of the following criteria:
Myelodysplastic syndromes, including any of the following:
Refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin lymphoma, or multiple myeloma
HLA-identical unrelated donor available
HLA-phenotypically identical for HLA-A and HLA-B alleles and identical for DRB1 alleles by DNA typing for both class I and class II antigens
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
Drug: cyclophosphamide · Drug: cyclosporine · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation · Radiation: total-body irradiation
Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
Drug: busulfan · Drug: cyclophosphamide · Drug: cyclosporine · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation
Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
Drug: cyclosporine · Drug: etoposide · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation · Radiation: total-body irradiation
Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
Drug: cyclosporine · Drug: fludarabine phosphate · Drug: melphalan · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation
Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
Drug: cyclosporine · Drug: fludarabine phosphate · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation · Radiation: total-body irradiation
Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
Drug: busulfan · Drug: cyclosporine · Drug: fludarabine phosphate · Drug: methotrexate · Drug: mycophenolate mofetil · Drug: sirolimus · Drug: tacrolimus · Procedure: allogeneic hematopoietic stem cell transplantation · Procedure: peripheral blood stem cell transplantation
Neutrophil Engraftment - The Days Till ANC Recovery
The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is \> 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment.
Time frame: Up to 180 days post transplant
Two-year Overall Survival
Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.
Time frame: Up to 2 years post transplant
Among the 260 enrolled patients, who consented to the study, 5 patients were not eligible.
| Milestone | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI |
|---|---|---|---|---|---|---|
| Started | 62 | 17 | 130 | 4 | 40 | 2 |
| Completed | 62 | 17 | 130 | 4 | 40 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is \> 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment.
| days | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI |
|---|---|---|---|---|---|---|
| Neutrophil Engraftment - The Days Till ANC Recovery | 17 (11 to 39) | 16 (13 to 21) | 15 (8 to 36) | 14 (14 to 17) | 18 (11 to 28) | 16 (16 to 16) |
Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.
| percentage of survival probability | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI |
|---|---|---|---|---|---|---|
| Two-year Overall Survival | 58 (45 to 69) | 50 (25 to 71) | 54 (45 to 62) | 50 (6 to 84) | 38 (23 to 52) | 50 (0.1 to 91) |
Collected over Adverse events were assessed up to Day 100 post-transplant. All-Cause Mortality was assessed from start of protocol treatment to death due to any cause, or last follow-up, whichever comes first, assessed up to 20 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen I | 45/62 (72.6%) | 4/62 (6.5%) | 14/62 (22.6%) |
| Regimen II | 14/17 (82.4%) | 1/17 (5.9%) | 4/17 (23.5%) |
| Regimen III | 103/130 (79.2%) | 7/130 (5.4%) | 38/130 (29.2%) |
| Regimen IV | 2/4 (50%) | 0/4 (0%) | 0/4 (0%) |
| Regimen V | 32/40 (80%) | 3/40 (7.5%) | 10/40 (25%) |
| Regimen VI | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) |
| Event | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI |
|---|---|---|---|---|---|---|
| Infection with unknown ANCInfections and infestations | 1/62 | 0/17 | 2/130 | 0/4 | 1/40 | 1/2 |
| Infection without neutropeniaInfections and infestations | 1/62 | 0/17 | 1/130 | 0/4 | 1/40 | 1/2 |
| Neuropathy: motorNervous system disorders | 1/62 | 1/17 | 0/130 | 0/4 | 0/40 | 0/2 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/62 | 0/17 | 4/130 | 0/4 | 2/40 | 0/2 |
| PlateletsBlood and lymphatic system disorders | 2/62 | 0/17 | 0/130 | 0/4 | 0/40 | 0/2 |
| Supraventricular and nodal arrhythmiaCardiac disorders | 2/62 | 0/17 | 0/130 | 0/4 | 1/40 | 0/2 |
| Bilirubin associated with GVHD for BMT studies, if specified in the protocol.Hepatobiliary disorders | 2/62 | 0/17 | 0/130 | 0/4 | 1/40 | 0/2 |
| Muscle weakness, generalized or specific area (not due to neuropathy)Musculoskeletal and connective tissue disorders | 2/62 | 0/17 | 0/130 | 0/4 | 0/40 | 0/2 |
| Somnolence/depressed level of consciousnessNervous system disorders | 2/62 | 0/17 | 1/130 | 0/4 | 0/40 | 0/2 |
| Rash/desquamation associated with GVHD for BMT studies, if specified in the protocol.Skin and subcutaneous tissue disorders | 2/62 | 0/17 | 0/130 | 0/4 | 0/40 | 0/2 |
| Event | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI |
|---|---|---|---|---|---|---|
| HypertensionCardiac disorders | 3/62 | 1/17 | 7/130 | 0/4 | 0/40 | 1/2 |
| ALT, SGPT (serum glutamic pyruvic transaminase)Investigations | 5/62 | 2/17 | 12/130 | 0/4 | 2/40 | 1/2 |
| Sodium, serum-low (hyponatremia)Investigations | 3/62 | 0/17 | 11/130 | 0/4 | 0/40 | 1/2 |
| Acute graft versus host disease (GVHD) (COH)Investigations | 4/62 | 0/17 | 19/130 | 0/4 | 2/40 | 0/2 |
| Graft versus host diseaseInvestigations | 3/62 | 0/17 | 17/130 | 0/4 | 2/40 | 0/2 |
| Glucose, serum-high (hyperglycemia)Investigations | 6/62 | 1/17 | 12/130 | 0/4 | 5/40 | 0/2 |
| Renal failureRenal and urinary disorders | 0/62 | 2/17 | 2/130 | 0/4 | 1/40 | 0/2 |
| Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT studies, if specified in the protocol.Gastrointestinal disorders | 6/62 | 0/17 | 15/130 | 0/4 | 3/40 | 0/2 |
| Fatigue (asthenia, lethargy, malaise)General disorders | 4/62 | 0/17 | 15/130 | 0/4 | 1/40 | 0/2 |
| Infection, Bacterial (COH)Infections and infestations | 3/62 | 0/17 | 14/130 | 0/4 | 2/40 | 0/2 |
| Age, Continuous(years) | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI | Total |
|---|---|---|---|---|---|---|---|
| Median | 38 (14 to 62) | 52 (12 to 62) | 50 (6 to 67) | 22 (18 to 42) | 37 (7 to 58) | 44 (41 to 47) | 44 (6 to 67) |
| Sex: Female, Male(Participants) | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI | Total |
|---|---|---|---|---|---|---|---|
| Female | 24 | 11 | 65 | 2 | 17 | 1 | 120 |
| Male | 38 | 6 | 65 | 2 | 23 | 1 | 135 |
| Race (NIH/OMB)(Participants) | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 2 | 0 | 8 | 1 | 2 | 0 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 1 | 0 | 0 | 4 |
| White | 55 | 17 | 118 | 2 | 38 | 2 | 232 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 0 | 1 | 0 | 0 | 0 | 5 |
| Region of Enrollment(participants) | Regimen I | Regimen II | Regimen III | Regimen IV | Regimen V | Regimen VI | Total |
|---|---|---|---|---|---|---|---|
| United States | 62 | 17 | 130 | 4 | 40 | 2 | 255 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2001 to primary completion in Mar 2007, 64 months.
Results were first posted in May 2023, 16 years 1 month after primary completion.
Of 74 non-industry phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 118. This study's 64 months is below that.
Counting every sponsor, half of 87 studies reached it within 68 months; a quarter within 37 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Busulfan · Cyclophosphamide · Etoposide · Fludarabine phosphate · Melphalan
Myeloproliferative Disorders →